A recent study led by researchers at the University of Nebraska Medical Center (UNMC) reveals a potential link between certain medications taken during pregnancy and an increased risk of autism spectrum disorder (ASD) in children. The research, published in the journal Molecular Psychiatry, analyzed data from approximately one-third of all US births from 2014 to 2023. It focused on sterol biosynthesis-inhibiting medications (SBIMs), commonly prescribed for conditions like high cholesterol and infections. The findings indicate that mothers who took at least one SBIM during pregnancy had a 1.47-fold higher risk of their child being diagnosed with autism compared to those who did not use these medications. The risk escalated with the number of SBIMs taken, reaching a 2.3-fold increase for those prescribed four or more. The study suggests that these medications may disrupt cholesterol synthesis, crucial for fetal brain development, although the exact mechanisms remain unclear. Experts advise pregnant women to discuss their medication use with healthcare providers to weigh the risks and benefits effectively. While the study offers valuable insights, it does not definitively establish SBIMs as a cause of autism, emphasizing the need for further research.